News
Summit Therapeutics Inc.'s faces FDA hurdles as its HARMONi study shows mixed results on ivonescimab. Click here to find out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback